Novaliq today launched its dry eye disease therapy, NovaTears, in New Zealand and said that it won registrational approval in Australia.
“NovaTears is a first-in-class treatment for this common and highly underserved ophthalmic disease,” Christian Roesky, Novaliq’s managing director & CEO, said in prepared remarks. “NovaTears is a clinically validated treatment that significantly improves signs and symptoms of patients suffering from dry eye disease. We know from our clinical studies that NovaTears immediately stabilizes the lipid layer and restores the natural tear film of the eye over time. I am confident that dry eye patients in Australasia will greatly benefit from this breakthrough innovation.”
The company has tested its therapy in four clinical trials, showing that NovaTears is safe and effective in patients with dry eye disease and meibomian gland dysfunction.
“We are thrilled to be able to offer patients a novel ophthalmic treatment that addresses signs and symptoms of evaporative DED and MGD,” CEO of AFT pharmaceuticals, Hartley Atkinson, added. “NovaTears is a first-in-class, water-free and preservative-free treatment that strengthens the lipid layer of the tear film thereby preventing evaporation. It is a welcome addition to our eye care line, one that will provide superior benefits to patients.”